United Kingdom · Delayed Price · Currency is GBP · Price in GBX Diaceutics Earnings Call Transcripts
Fiscal Year 2026
-
H1 2026 revenue grew 20%, while ARR reached GBP 29.4m with 149% NRR and 6% gross ARR churn. Precision for All and Relay expansion, pricing opportunities and AI-led efficiency underpin the growth strategy.
Fiscal Year 2025
-
Revenue grew 20% year-over-year with a return to profitability and strong adjusted EBITDA margin, despite challenging pharma market conditions. Strategic investments in data and expansion into new therapeutic areas support future growth and margin expansion.
Fiscal Year 2024
-
2024 marked a breakout year with 39% revenue growth, strong recurring revenue, and major U.S. expansion. The business is shifting to profitability in 2025, driven by new enterprise contracts, PMx solution launches, and robust order book visibility. Growth is underpinned by high margins, a leading pharma client base, and continued investment in AI and data.
-
Delivered strong H1 2024 growth with 24% revenue increase and 87% gross margin, driven by automation, new product launches, and the transformative PMX deal. Outlook remains positive with a focus on profitability in 2025 and expansion into rare diseases and Europe.
-
Transitioning to a high-margin, recurring revenue model, the business leverages a proprietary global lab network and AI-driven DXRX platform to deliver daily insights for pharma clients. Strategic partnerships, expanded operations, and a robust roadmap position it for growth in oncology and non-oncology markets.